Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG5266片在健康受试者和原发性胆汁性胆管炎（PBC）患者中的I/II期临床研究
CTR20213004Phase 2Terminated
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Nov 2021; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20213004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213004.